KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Outstanding (Weighted Average) (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $131.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 2.63% year-over-year to $131.0 million, compared with a TTM value of $131.0 million through Dec 2025, up 2.63%, and an annual FY2025 reading of $131.0 million, up 2.63% over the prior year.
  • Shares Outstanding (Weighted Average) was $131.0 million for Q4 2025 at Alnylam Pharmaceuticals, roughly flat from $130.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $131.0 million in Q4 2025 and bottomed at $117.1 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $124.3 million, with a median of $124.7 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) rose 4.0% in 2021, then grew 1.42% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $118.5 million in 2021, then rose by 2.73% to $121.7 million in 2022, then rose by 2.64% to $124.9 million in 2023, then grew by 2.2% to $127.7 million in 2024, then rose by 2.63% to $131.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ALNY at $131.0 million in Q4 2025, $130.6 million in Q3 2025, and $130.6 million in Q2 2025.